PHENTERMINE (cas 122-09-8)☆
-
Add time:09/07/2019 Source:sciencedirect.com
Phentermine is an indirect-acting, sympathomimetic amine used in the treatment of obesity. A central nervous system stimulant, phentermine increases heart rate and blood pressure and decreases appetite. It can induce physical and psychological dependence. It is used alone or in combination with topiramate.
We also recommend Trading Suppliers and Manufacturers of PHENTERMINE (cas 122-09-8). Pls Click Website Link as below: cas 122-09-8 suppliers
Prev:Case reportPHENTERMINE (cas 122-09-8) and Coronary Vasospasm–Induced Myocardial Infarction
Next:Clinical ScienceEffects of liraglutide plus PHENTERMINE (cas 122-09-8) in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Study protocol and rationale for a randomized double-blinded crossover trial of PHENTERMINE (cas 122-09-8)-topiramate ER versus placebo to treat binge eating disorder and bulimia nervosa09/25/2019
- Case ReportParadoxical topiramate-induced hyperphagia successfully treated with PHENTERMINE (cas 122-09-8) in a woman with migraine09/24/2019
- Clustering of PHENTERMINE (cas 122-09-8) HCL Drug from Online Patient Medication Reviews09/10/2019
- Original articleUse of PHENTERMINE (cas 122-09-8)-topiramate extended release in combination with sleeve gastrectomy in patients with BMI 50 kg/m2 or more09/09/2019
- Clinical ScienceEffects of liraglutide plus PHENTERMINE (cas 122-09-8) in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial09/08/2019
- Case reportPHENTERMINE (cas 122-09-8) and Coronary Vasospasm–Induced Myocardial Infarction09/06/2019
- Lorcaserin vs. PHENTERMINE (cas 122-09-8) among non-surgical and surgical obese patients: Anthropometric, glycemic, lipid, safety and cost outcomes09/05/2019
- Letter to the EditorPHENTERMINE (cas 122-09-8) associated recurrent intracerebral hemorrhage09/04/2019